» Subscribe Today!
More of what you want to know.
The Daily News
X

Forgot your password?
Skip Navigation LinksHome > Name & Property Search
Search results for 'Mylan' | Search again
DeSoto Public Records:0
Shelby Public Records:4
Editorial:6
West Tennessee:0
Middle Tennessee:3
East Tennessee:2
Other:0

You must be a subscriber to see the full results of your search.

Please log in or subscribe below if you are not already a subscriber.

The Daily News subscribers get full access to more than 13 million names and addresses along with powerful search and download features. Get the business leads you need with powerful searches of public records and notices. Download listings into your spreadsheet or database.

Learn more about our services | Search again


Editorial Results (free)

1. Supreme Court Weighs Generic Drug Dispute -

WASHINGTON (AP) – The Supreme Court seems divided as it considers a high-stakes patent dispute between rival pharmaceutical companies over the world's best-selling multiple sclerosis treatment.

2. Supreme Court Takes Up Drug Company Dispute -

WASHINGTON (AP) – The Supreme Court is wading into a patent dispute between rival pharmaceutical companies over a multiple sclerosis treatment.

The justices agreed Monday to hear an appeal from Teva Pharmaceutical Industries Ltd., which claims the U.S. Court of Appeals for the Federal Circuit wrongly overturned five of its patents for the drug Copaxone.

3. FDA: New Suppliers to Ease 2 Cancer Drug Shortages -

TRENTON, N.J. (AP) – Federal regulators have approved new suppliers for two crucial cancer drugs, easing critical shortages that had been ratcheting up fears that patients, particularly children with leukemia, would miss lifesaving treatments.

4. Ranbaxy Gets Final FDA OK for Generic Glaxo Drug -

NEW YORK (AP) - Generic drugmaker Ranbaxy Laboratories Ltd. said Tuesday its U.S. subsidiary received final U.S. Food and Drug Administration approval on two generic doses of the migraine drug Imitrex.

5. Archived Article: Claritin P2 - Claritin copycats might hit market soon

Claritin copycats might hit market soon
A federal judge ruled patent claims on a derivative of allergy drug Claritin are invalid, a decision that could enable rival firms to sell copycat forms of Scher...

6. Archived Article: Benchmark - Court ruling might

Court ruling might

hurt consumer suits

A federal appellate court decision on a contested patent extension for Bristol-Myers Squibb Co.'s anti-anxiety drug BuSpar might aid the drug company's defense in upcoming lawsuits f...